RA Capital Management, L.P. and affiliated reporting persons filed a Form 4 on November 2, 2026, disclosing the sale of approximately 2.718 million shares of LENZ Therapeutics, Inc. common stock on October 29, 2026.

Key Highlights

  • Three sale transactions: RA Capital-affiliated entities disposed of 2,159,516, 451,998, and 107,170 shares of common stock, all on October 29, 2026.
  • Weighted average price: All three transactions were reported at a weighted average price of $3.36 per share, with individual sales ranging from $3.16 to $3.58 inclusive.
  • Post-transaction holdings: Following the sales, beneficial ownership stands at 1,159,823 shares held via RA Capital Healthcare Fund LP, 242,757 shares via RA Capital Nexus Fund II, L.P., and 57,559 shares via a separately managed account.
  • 10% owner status: All reporting persons - RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev Shah - are identified as 10% owners of LENZ Therapeutics, Inc.
  • Joint filing: The form was filed jointly by more than one reporting person, including the investment adviser, the fund entity, and managing members Peter Kolchinsky and Rajeev Shah.
  • Disclaimer of beneficial ownership: According to the filing, each reporting person disclaims beneficial ownership of the reported securities "except to the extent of its or his respective pecuniary interest therein."

RA Capital Management's October 29, 2026 Dispositions in LENZ Therapeutics

According to the Form 4 filed with the SEC on November 2, 2026, RA Capital Management, L.P., acting as investment manager, oversaw the sale of LENZ Therapeutics, Inc. (NASDAQ:LENZ) common stock across three separate line items on October 29, 2026. The transaction code recorded for each sale is "S," indicating open-market sales. The shares were sold at a weighted average price of $3.36, with the filing noting that actual transaction prices ranged from $3.16 to $3.58 inclusive across multiple transactions.

The filing identifies the shares as held indirectly across three vehicles. The largest block, 2,159,516 shares disposed of, was held directly by RA Capital Healthcare Fund, L.P. A second block of 451,998 shares was held by RA Capital Nexus Fund II, L.P., and a third block of 107,170 shares was held by a separately managed account. Following all reported transactions, the filing discloses remaining beneficial ownership of 1,159,823 shares, 242,757 shares, and 57,559 shares in those respective vehicles.

The reporting persons include RA Capital Management, L.P. as investment adviser, RA Capital Healthcare Fund LP, and managing members Peter Kolchinsky and Rajeev Shah, all of whom are listed as 10% owners of the issuer. The general partner of the adviser is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are described as managing members. The filing was signed by Peter Kolchinsky in multiple capacities and by Rajeev Shah individually, each dated November 2, 2026.

What Was Disclosed

RA Capital Management, L.P. and affiliated reporting persons disclosed the sale of a combined 2,718,684 shares of LENZ Therapeutics, Inc. common stock on October 29, 2026, at a weighted average price of $3.36, with post-transaction holdings reported across three investment vehicles.